Literature DB >> 15308104

IL-22 increases the innate immunity of tissues.

Kerstin Wolk1, Stefanie Kunz, Ellen Witte, Markus Friedrich, Khusru Asadullah, Robert Sabat.   

Abstract

Interleukin 22 (IL-22) is mainly produced by activated Th1 cells. The data presented here indicate that neither resting nor activated immune cells express IL-22 receptor, and IL-22 did not have any effects on these cells in vitro and in vivo. In contrast, cells of the skin and the digestive and respiratory systems represent putative targets of this cytokine. The expression of IL-22 receptor in keratinocytes was upregulated by Interferon-gamma. In these cells, IL-22 activated STAT3 and directly and transcriptionally increased the expression of beta-Defensin 2 and beta-Defensin 3. High levels of IL-22 were associated with strongly upregulated beta-Defensin expression in skin from patients with T cell-mediated dermatoses. Taken together, IL-22 does not serve the communication between immune cells but is a T cell mediator that directly promotes the innate, nonspecific immunity of tissues.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308104     DOI: 10.1016/j.immuni.2004.07.007

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  546 in total

Review 1.  Structure and function of interleukin-22 and other members of the interleukin-10 family.

Authors:  Daniela Barretto Barbosa Trivella; José Ribamar Ferreira-Júnior; Laure Dumoutier; Jean-Christophe Renauld; Igor Polikarpov
Journal:  Cell Mol Life Sci       Date:  2010-05-08       Impact factor: 9.261

2.  Interleukin-22 regulates the complement system to promote resistance against pathobionts after pathogen-induced intestinal damage.

Authors:  Mizuho Hasegawa; Shoko Yada; Meng Zhen Liu; Nobuhiko Kamada; Raúl Muñoz-Planillo; Nhu Do; Gabriel Núñez; Naohiro Inohara
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

Review 3.  Innate immune signaling in defense against intestinal microbes.

Authors:  Melissa A Kinnebrew; Eric G Pamer
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

4.  Membrane-bound IL-22 after de novo production in tuberculosis and anti-Mycobacterium tuberculosis effector function of IL-22+ CD4+ T cells.

Authors:  Gucheng Zeng; Crystal Y Chen; Dan Huang; Shuyu Yao; Richard C Wang; Zheng W Chen
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

5.  IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist.

Authors:  Frank L van de Veerdonk; Angela K Stoeckman; Gouping Wu; Aaron N Boeckermann; Tania Azam; Mihai G Netea; Leo A B Joosten; Jos W M van der Meer; Ruyi Hao; Vassili Kalabokis; Charles A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

Review 6.  A tale of two cytokines: IL-17 and IL-22 in asthma and infection.

Authors:  Michelle L Manni; Keven M Robinson; John F Alcorn
Journal:  Expert Rev Respir Med       Date:  2013-12-10       Impact factor: 3.772

7.  Distinct regulation of interleukin-17 in human T helper lymphocytes.

Authors:  Zhi Chen; Cristina M Tato; Linda Muul; Arian Laurence; John J O'Shea
Journal:  Arthritis Rheum       Date:  2007-09

8.  Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment.

Authors:  Szu-Yuan Pu; Fei Xiao; Stanford Schor; Elena Bekerman; Fabio Zanini; Rina Barouch-Bentov; Claude M Nagamine; Shirit Einav
Journal:  Antiviral Res       Date:  2018-05-16       Impact factor: 5.970

9.  Tissue-expressed B7-H1 critically controls intestinal inflammation.

Authors:  Lisa Scandiuzzi; Kaya Ghosh; Kimberly A Hofmeyer; Yael M Abadi; Eszter Lázár-Molnár; Elaine Y Lin; Qiang Liu; Hyungjun Jeon; Steven C Almo; Lieping Chen; Stanley G Nathenson; Xingxing Zang
Journal:  Cell Rep       Date:  2014-02-13       Impact factor: 9.423

Review 10.  Role of MDA-7/IL-24 a Multifunction Protein in Human Diseases.

Authors:  Mitchell E Menezes; Praveen Bhoopathi; Anjan K Pradhan; Luni Emdad; Swadesh K Das; Chunqing Guo; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.